11,846 Results

Brilinta monotherapy reduced the risk of clinically relevant bleeding compared to aspirin + Brilinta in high-risk coronary patients according to phase IV independent TWILIGHT trial. AstraZeneca

 Added 1 day ago

Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced...

FDA approves supplemental sBLA for Taltz to treat pediatric patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.- Eli Lilly

 Added 1 day ago

Eli Lilly and Company announced the FDA has approved a supplemental Biologics License Application (sBLA) for Taltz (ixekizumab) injection, 80...

STRIDE-1 Phase III Trial of AXS 05 meets key secondary endpoints in depression.- Axsome Therapeutics

 Added 1 day ago

Axsome Therapeutics announced that AXS 05 (bupropion + dextromethorphan) met key secondary endpoints in the STRIDE-1 trial by rapidly and...

EU approves Nubeqa for castration-resistant prostate cancer .- Orion + Bayer

 Added 1 day ago

The European Commission has granted marketing authorisation in the European Union (EU) for Nubeqa (darolutamide), an oral androgen receptor inhibitor...

Phase III ELIPSE HoFH trial results of REGN 1500 met primary endpoint in homozygous familial hypercholesterolemia.- Regeneron Pharma

 Added 1 day ago

Regeneron Pharmaceuticals announced that detailed Phase III ELIPSE HoFH trial results of REGN 1500 (evinacumab) in patients with homozygous familial...

Phase III ODYSSEY HoFH trial of Praluent meets primary endpoint in homozygous familial hypercholesterolemia.- Regeneron Pharma

 Added 1 day ago

Regeneron Pharma has presented Phase III ODYSSEY HoFH trial results from a late-breaking presentation, demonstrating the effect of Praluent (alirocumab)...

DAPA-CKD trial for Farxiga is stopped early in patients with chronic kidney disease due to overwhelming efficacy.- AstraZeneca

 Added 1 day ago

The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for Farxiga (dapagliflozin) in patients...

FDA approves Imfinzi as first line treatment for extensive stage small cell lung cancer.- AstraZeneca

 Added 1 day ago

Imfinzi (durvalumab) from AstraZeneca has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small...

Farxiga phase III DAPA-CKD trial will be stopped early after overwhelming efficacy in patients with chronic kidney disease.-AstraZeneca

 Added 1 day ago

The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for Farxiga (dapagliflozin) in patients...

Phase III VICTORIA study of BAY 1021189 shows reduced risk of hospitalisation or death in heart failure.- Merck Inc + Bayer Healthcare

 Added 2 days ago

Merck Inc announced the presentation of results from the VICTORIA trial, a Phase III study evaluating the efficacy and safety...

Load more